Novartis (Taiwan) Co., Ltd.
|Title of Study||
A Prospective, Non-interventional, Multi-center, Surveillance Study to Observe the Tolerability of Exjade® (Deferasirox) in Patients with Myelodysplastic Syndrome (MDS) for Chronic Transfusion-Related Iron Overload
To explore tolerability of Exjade® as chelation therapy through measuring AE-related discontinuation rate in routine clinical practice in MDS patients at 6 months.
|Number of Sites||
|Period of Study||
From：Aug.1, 2015 to：Aug. 31, 2019
|Number of Patients||
|IRB Approval Date||
Sep. 17, 2015 (1st IRB approval date)
|Publication Plan / Date||
Aug. 31, 2020